Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. Welcome to Verona Pharma's First Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a mode. Earlier this morning, Verona Pharma issued a press release announcing its financial results for the 3 months ended March 31, 2023. A copy can be found in the Investor Relations tab on the corporate website, www.veronapharma.com.

like the you and company's forward-looking I'd call, during prospects begin, statements. about statements future we to that remind today's are Before expectations, plans management's statements expectations. based forward-looking on These are current

represent promises nor conference and the expectations results, estimates expressed from the uncertainties factors management's performance These statements achievements important forward-looking statements. are guarantees involve Any be unknown of other our known cause date may -- by call. our to the or forward-looking as and such that or implied risks, and actual statements of different neither materially of this

While to future, may to it change. statements events so, forward-looking the obligation the any subsequent company do to update some such disclaims even in views elect its point if at cause

reminder, Please will is Dr. days. ahead. a the this XX for to Officer. and to call now over available Executive go recorded I'd Chief being remain like David Zaccardelli, turn call As

David Zaccardelli

today to Medical Thank Hahn, Officer; everyone, Chief Vice you, Martin, Financial and and our our President welcome, With Chris today's our are Dr. Rickard, Commercial. Chief Senior Mark Officer; Kathy of me call.

ensifentrine States. During quarter. second ENHANCE Phase the on the quarter data the regulatory COPD to pre-NDA to of and comprise from quarter, the successful we remain the subjects. from nebulized ensifentrine III progress treatment content on later X,XXX an We update FDA forward we substantial the submit look schedule NDA program maintenance meeting submission will We clinical and package. United recently The this providing including approximately first NDA the of other had NDA in and aligned the with to for studies make in the planned safety data of our that are the towards continued for a believe

launch commercial December HR, August positions proceeding in data and In and finance adding activities efforts operations. ENHANCE-X parallel, planned. across we our market the reporting ENHANCE-X XXXX, and leadership announcing positions IT affairs after pre-commercialization XXXX, leadership across and in data as commercial, in medical adding positive our these After access we are began and U.S. efforts our functions teams deepened marketing, expanded and commercial compliance key

Our to be XXXX. we in potential prepare in MOA efforts the ensifentrine setting are novel in the half of launch XX market the continue second of the for pre-commercialization the COPD first accelerate the These ensifentrine, has for treatment maintenance years. the as to potential efforts of launched for critical which over stage

China, first partnering trial treatment month, for Pharma, Turning Greater subject strategy. they enrolled to in their our Last the Phase in Nuance China. COPD in global the announced development III of maintenance partner our ensifentrine evaluating

need change begin Drug We Nuance and look as Pharma and exclusive approved, for Nuance to the these a global for ensifentrine commercialize role such, for right COPD. in to III treatment in Greater Phase in for key to I as addressing a forward has studies believe Evaluation As providing updates the studies and has will clearance the treatment ensifentrine and we for with progress. if novel COPD. China, previously Pharma to Center further received China, ensifentrine, paradigm a China's play reminder, COPD develop potential from Phase

ensifentrine closer exacerbation. to of ensifentrine these providing met brings our The in statistically significant treatment our risk to NDA us and population trials was towards lung rate new the demonstrating in urgent clinically positive. and effective patient of a the submitting need ENHANCE-X, ENHANCE remarkable both in from reductions of highly work a for success option. And endpoints improvements as successfully III data well The function Phase in and as program ensifentrine primary ENHANCE-X and the meaningful

month. Thoracic announced analysis presenting from at American ENHANCE later the additional Society the to looking forward study this earlier month, this As International we are Conference

healthcare abstracts trial exacerbation, XX use pooled safety. symptoms, symposium rescue present quality of analysis ENHANCE-X medication, clinical and life and and will of covering data on from We utilization subgroup ENHANCE-X and a

An symposium are overview May Medicine. on and trial presented for of the breakthroughs. of and ENHANCE trial reserved of Critical issue the results website abstracts published American The new the highlighting ATS of will in Respiratory Journal as be part the the Care clinical

to death. approved, We it XXX will as require will XX% May a of worldwide. therapies we hosting existing conference patients patients mechanism availability is COPD COPD third discuss for provide more and XX, million treatment, advance and Despite symptoms also the new COPD more these selective be relief physicians Currently, the than and a patients. month, effective their call to believe its of and PDEX cause And from be webcast leading on if Tuesday, transformational data. suffer of experienced for PDEX approximately the a ensifentrine, patients. treatment days to in COPD novel With action XX per of inhibitor, than

as In another our pivotal to COPD. delivering patients ensifentrine we we advance XXXX be mission towards Verona conclusion, expect of year for with to

turn I review to results call quarter. our for the will now financial first Mark the over to

Mark Hahn

launch of sufficient facility, under planned at XXXX, expect ended and through the our and quarter loan and available remains approval. the ensifentrine strong sheet balance tax with runway We everyone. pending the $XXX.X expected of we credit with end program funding and equivalents. from to receipts have the U.K. XXXX the on the United regulatory Thank cash of expected States million believe commercial We including in Dave, morning, you, to Oxford hand, the good first currently be in least cash

$X.X ordinary activities the net of first million per quarter tax to costs million compared for in costs period share For quarter XX, period or a the million a same represents March of the ENHANCE ordinary compared development ended reported of or on per XXXX other was for to $XX.X XXXX QX a after were was first the primarily Phase was III $X.XX and the per tax $XX.X $X.XX related share and for This in loss million per the for a March after loss $X.XX decrease XXXX. data XXXX. quarter development ATS ended and for $X.XX quarter of ATS Research net focused compared the XXXX, of the of to quarter trial XXXX. loss heavy million QX as $XX.X decrease enrollment of XXXX, analysis The the trial due to XX, and clinical $XX.X finalizing program. was loss

general were well compensation for as due of was This Selling, a in infrastructure Ligand in for million increase prepare quarter partially to $X of increase launch. XXXX. for the to March build-out an the expenses The first agreement, reported as our $X.X primarily nonrecurring and we of million million potential a commercial in during was commercial incurred the of increase million to XXXX related $X.X compared administrative increase including the cost as XXXX. same quarter expenses to period in SG&A was $X.X share-based which XX, the million related costs, people-related the by ended our charge modification offset $X.X

for now I'll to turn the call the over Q&A. operator back the

Operator

[Operator Instructions]

is Rahimi Sandler. question Yasmeen first Piper with The from

Unidentified Analyst

is guys. This Lauren Yas. on for Hi,

Just questions us. a for few

discussions? meeting? you could is received the what of you First, then and pre-NDA on meeting comment pre-NDA completion type And strategic feedback in important how of your

David Zaccardelli

Hello and Yes. good morning.

handling administrative highly we expected agency the to the meeting in structured were certain see wanted would So nature data around, -- really was content, in regarding what say, certain as I pre-NDA how areas.

and mentioned aligned difficult, of rather content just the was was or there regard format with sure that to that, the the press we anything as making but problematic and NDA. like confirmatory we so And that were release in the nothing

think submitting said, all these projection So impact I second had And an typically of should quarter. on covered we're the in again, many meeting to, the timeline think position some activities in item in depending topics I as With meetings. meet think the to we I partner. pre-NDA I as regard a good partnering, you as for our

difficult all helpful with and it's really, assess So exactly. in our progress that are is But of partnering. think these to I us, continual activities

Unidentified Analyst

is one It major such -- just I color Well, important, program. a all clinically little guys bit the course. the you think conference Great. important timing that And conference of of after for with there. ENHANCE was had posters, XX getting really first ATS the Why a maybe we from is the data really just more.

very think So I timing nice. worked out

history data right the regard with forum, have that to and think can mentioned, the different we're all the a And ATS of strong well the of sharing lot between analyses that excited in making subset I ENHANCE-X I sure We we provide study. as pooled we about very data at transparency, we're as ENHANCE-X all very analyses. also that a

be everyone to encourage So there. I do

the an enhanced to highlighted be I all exciting generated is program. ensifentrine going the we've specifically that a be years going data to think where and time. moment really it's for an over And

forward for sure, ensifentrine So it. a big and moment to look we for

Operator

Securities. Wedbush The Andreas is next with from Argyrides question

Andreas Argyrides

for to on morning. question was asked good ATS. Yes, the Hey, that follow questions. And our thanks up just taking

you have how And submitting posters are to a are then commercial you there, and framing gating of framing this therapy? sits How the You patient for lot ensifentrine in, -- thinking the opportunity analyses. what some in about you're or are how ideal the where population have the factors NDA? they subgroup

David Zaccardelli

Andreas. Sure,

for take I'll comment commercialization. Let sort to one him of me the our then on to turn second it over and Chris first,

that which an in -- the think the I massive is for together. it interrelated the items NDA and is the And documents is. program, just what documents document, gating NDA substantial sub that a putting totality, is

And that. time, made team done done together And progress. They been off same an we've be the must of And diligently the as as far you do concurrently. incredible items other they to feed some each put NDA. so has as the when content at can't be the working consecutively

an that want And of that and NDA. involved together to so the the it's magnitude that of putting if of gating, in work are And done up event understands it, that all streams maybe more just call workload. you is who've that and really one lining

progress. quite So the that's at, and we're pleased with we're where

So over with that, I'll to turn Chris. it

Christopher Martin

posed I Dave. question fits the Andreas, ATS appreciate that ensifentrine where and you about in. Thanks

great population. consistency COPD things show be of how I ensifentrine think ATS conference about continues of patient in is the the there the one up a that to will coming highlighted performs data the

symptoms at trials, I and is we've it early then and the and X sustained this also have improvements, also separates X being in response of will in ensifentrine, ATS attracted we of where from seen quality which life physicians think our bronchodilation, when research, that's risk which market and exacerbation but ENHANCE reduction, the lung data but in placebo but that the produced of also see be function out seen weeks. the to at you seen you shown data, look in between acute

that the an physicians that are mechanisms extremely there. you from complementary of totality current out a a you ensifentrine to profile, research seeing market standpoint, when what take really see So as is product

current therapies. as to ensifentrine those using they're that So symptomatic our all in research market an on patients remain add-on

of I of of things up one about burdens until population they're still and is potential the And still XX-plus approval they're in today using COPD years. they've that exacerbations. we ensifentrine, MOAs know with think patient the that symptoms, the struggling doctors struggling that been been the have limited for daily the risk of with

excited they a they patient. are in for when on kind needed very additional weapon much see treatment that the patients symptomatic So extraordinarily a provide and of paradigm their alternative physicians basis health, in could in come are ensifentrine, see new of that of the that regular ensifentrine a and profile in need a

So we patients of on therapies. symptomatic the usage are ensifentrine current COPD across see broad very that

Operator

The question Securities. SVB with Risinger is David next from

David Risinger

Good morning, very David Thanks team. much. and

So two I have questions.

the adoption color on in and between of an of the go-forward could II development more programs provide vision other then your Phase your First, commercial prescribers? R&D ensifentrine, second, including And $XX.X versus some spending mix prescribing update the provide for you on could pulmonologists million to expected quarter? first relative you

David Zaccardelli

the just maybe David, and Mark on the Phase comment comment comment briefly on Chris question. then commercialization can programs. can I'll on spend II

the around partners around XXXX through bring referring I makes I example, on making the that guess, do help me to to that with are sure our asthma, ensifentrine for the So in devices, We to forward asthma for our for have. to progressing cystic forward. pharmacology, to careful look laser-focused and fibrosis which move offering been of and They're proprietary specifically these would you we look example, COPD for we indications, other be continue II in programs, and forward. know, progress the And the sense size expertise, We've think us focused very tremendous to devices a other development on we'll property for all possibly in really continue stay indications. Phase since we you to beginning that. opportunities as indication, ensifentrine based do ensifentrine as joining XXXX we COPD the great DPI we intellectual being as specifically MDI, space, advantageous sure,

COPD, fits we dual well allows in and very as would partnering are see our So do great differences we think very clarity treat we a for doesn't with physicians in progress, forward which that with at bronchodilator 'XX. nebulized I find through really in for fits step not nebulized But to expect patients LAMA get as the we a think 'XX and you'll I our around great with anti-inflammatory to progressing activity and that. that's a strategy And exist. a well. pharmacology I into comment us that different pharmacology, nicely and want product ensifentrine more look combination how product, 'XX as ensifentrine to continues

XXXX about hear you'll through as so And well. progress as we that more

want I'll that, with to anything talk regard now, with to you do about So Mark, spend? ask

Mark Hahn

Yes.

a thoughts. formulation to we're III related and I'll work. lingering just There's IQVIA to work there costs combination the call some as to on the doing that that mentioned, we're as couple is study. program product, costs Dave One also, some some, of wrap-up early with related the are other continuing So of suppliers Phase

So on on fee work filing be incurred dollar some, there's then there quarter it, will spends NDA CMC going the batches. that this would I validation And be some call do there's we course, And of then, will small as well. as the that.

over probably of QX. perspective, it year. and in QX the still as the QX tapering could So still be from spend it will But we as million I will balance much be you $XX.X down think -- it be then look fairly at get a significant through the lower and

Christopher Martin

the can answer and for of And on here, adoption David, the the then think color what I mix comment and you. we

at size most the ensifentrine are on about we market believe and appropriate the reps about see of that that are are for sales we ensifentrine. think XXX and driver believe, pulmonologists, to use early we to prescribers our force as ensifentrine. From we the patient So with that the reach adoption opportunity utilization launch, ensifentrine what research, likely is the

we there adoption treatment influential from call nurse and of point patients be but assistants but COPD. within access in where believe prescriber physicians be easily, some potentially the we like ensifentrine. acting number, not So we That in the there as practitioners are not about there's are calling also physician the and patient, primary -- right way launch. stages pulmonology, initial be important segments quite and are our that would primary care of that prepare size able the the to areas one adoption that XX,XXX XX,XXX organization are of handle what of certain focus XXX some large believe will are those -- the will are we at community. will launch have we a do the of for -- the that growing be country a and And but COPD to nurse to within the for all also very ensifentrine. that reps critical pulmonologist again, areas, pulmonology on to PAs, about And in with And then a we XX,XXX believe doctors that believe type largest is

Operator

is from Tom question Shrader BTIG. next with The

Thomas Shrader

questions. the Thanks morning. taking for Good

to people in who drug then in their want is launch? it people minds. of wildly of disparate sort the to pile of possible what publication done KOL use and for of day patients answers. get as we related probably sense Chris, changing the on lot I a and what patients work, X/X you're say the serious We feedback like? most on getting for their compelling is with Or if data a a who as curious X talking And sitting wondering people your and only. I'm You're get same schedule and it wait question, closer And to data. your looks minds? we've make And I'm to in soon think does

David Zaccardelli

that well. as comment data, It that opine do much of are ask So is mountain mentioned, just and have a to -- as come Kathy well ATS. at is I'll a on as to you out we brief of strategy, publication going we

We publication. have the submitted enhanced

want would I we if, as you the comment don't expect Kathy, publications future, out in come But would don't that then course, and much. to overall progress. timing to of so we to control near specifically. expect And come And on to out we relatively very hopefully. And that continue know ATF the we

Kathleen Rickard

with is say, ahead All right. as and waiting we're for they submitted go that. enhanced data Well, the the

And worked other out to as coming we ensifentrine. many of that different be don't control various those, but now have of background couple the a Also were formal to We presented recently. those forms further says, publications publications of all and the of that Dave the anticipate timing at submitted of those will were again, recently. data ATS, journals profile the into scientific enhance we

to of it's also probably understand the U.S. think meeting particularly respiratory very the world, that ATS in leading around is important scientific I the experts all

And publications anticipate and that very all to so those received, of with be being we'll well there that we data data. will for continue proceed presented

David Zaccardelli

you do market to about Chris, want our research? talk And

Christopher Martin

ensifentrine and thing too. One ensifentrine, research significant we the ENHANCE have for mentioned, amount from we Thanks, mountains we now the question. have you on Yes. market as data -- Tom, Dave, studies, of thanks, a on of

the use ensifentrine is answer, saw is which being. and few the that in I to how we've course talking HCPs the data, what they over very of think ensifentrine within and And almost they'll in that consistency ensifentrine market last there's of seen what the close the see years X,XXX thing to we're they about clinical potential between we how similar XXX research. in

a potential be what to is in has mechanism practice. think novel added that the symptomatic patients many they that are can ensifentrine be see to their I

serious patients that's choices you symptomatic. place very of those in first as is population. on maybe are We of As they to them the they use therapy significant places physicians a that market, triple number there no use, or we that think the one the mentioned, choices on that to have KOLs, patients of the on using know those patient limited there's dual those ensifentrine top patient, talk have or other out and to in about

ENHANCE-X out symptoms from exacerbations, function lung come the paradigm. the ENHANCE started to earlier of and consistency moving into we went and treatment data But you the has on the the data as and saw physicians ENHANCE-X drug

So they're a trials. looking to bronchodilator LABA really is the the the of logical a say come ICS, that's X United almost clinical next X at these given single on in maybe million patients million patients they which ensifentrine, States. And out or data choice the is

physician's So minds you second first in population broader see well. and that then as that much being the the sometimes patient patient

that's which function I worried it's the points think and and on other they're shows symptoms the profile key data really with the profile, at placebo. about that to thing you that that's similar comparable early safety of a physicians about, but between or measures compelling asked lung sustained balance exacerbations, a efficacy balanced important, that's all to, response point risk

mechanism get without a this So profile physicians the novel can much taking of risk.

is to to short find going work period well. quick be in going decisions them in they're the patient to of population make most these allows cases, out very the able And and to within and time product choices adding how ensifentrine a that as to patients. So

Operator

with The from Pachaiyappan Wainwright. Boobalan next question is H.C.

Boobalan Pachaiyappan

morning, progress. questions A Good the few team. Congrats from on us. Hi.

CMC filing, the outstanding to radar? they any NDA comments FDA ISE the regarding speak clarifications you applicability communicate has [inaudible] can issue whether us about provided or and their sections Firstly, particularly ISS, in did and of for data any

David Zaccardelli

we to ISS. with would Of cover regard course, general ISE, concepts

sure how see example, we clarification, about from the and they the understood those quarter. to CMC us related And as mentioned, is mentioned, I've as For there again, and were in alignment, of to approach confirmation different meetings also is us sections. proceeding the going topics we prohibiting as Much had we well. from in making topics nothing the submission were, that with second I information

very meeting a So I do. supposed -- to what with progress accomplish our pleased for think what again, and pre-NDA and exactly it's

Boobalan Pachaiyappan

preliminary with excited any ensifentrine with improvement in about opportunities you Can respect label you And had or agency are Okay. label? what more the the share also you expansion discussions to future?

David Zaccardelli

incredibly premature it's talk think I to the mean I about label. Yes.

a think you'd as is review expect. that everything issue, I

And so label as we the will will view we the submit review and commence. what then

again, So I we'll think, wait on that.

the for in many are As think far us. expansion label, there as I opportunities

think I to see where end first we we up. need

Of great with for I of expansion process mentioned, COPD course, as at in maximum allow indications, for utilized looking patients are a example, products extract the the as to this be combination to as as as other think from continue well of for end with LAMA, I well ensifentrine and other to a benefit ensifentrine. as to ensifentrine opportunities

think I progress lot there's So we it. with of a as opportunity

Boobalan Pachaiyappan

Okay. one one, last Maybe maybe Kathy, for sorry. Katie.

stake curious Maybe hear in COPD ensifentrine up data that just thoughts in performance? on does treatment. your So of off-label how COPD could exacerbation then how biologics against to staying And this adoption? ensifentrine impact lane, use your Dupixent in

David Zaccardelli

that? want do Kathy, to talk you about

Kathleen Rickard

Sure.

I think being are populations need are studied to of you patients there very that that here. different understand

only multi at patients. So having very patients those are DUPIXENT really who looks exacerbations the severe in

patients in of have spectrum the for so end who an effect have on the really And they that.

population as The the So COPD difference very looking all very general COPD of we're limited that at of the it's a we is treat patients pulmonologist. ensifentrine small population.

as to show for mentioned, population, PAs, patients day and lot So general of pulmonologists having exacerbations symptoms, of in the who primary have are by are very but or that physicians, significant in that problems. that's significance the who a that enhance an or and X this have care not we Chris have exacerbation population COPD year, may which in have every have of in lot X a didn't patients a exacerbations. decrease able we And is to U.S. the may NPs treated

a patients And is who are enhance they for products why because many the show they having many can't exacerbations. unless that reason difference do

products, of Dupixent hope applicable to So is, portion population. patients COPD the whereas COPD including of small applicable to the a I all many helps. there, it's only relevance that out certain are think ensifentrine I

Operator

comes Lee question with The from next Truist. Joon

Joon Lee

thanks for questions. our Hey, taking

As with alluded from the XXX wouldn't than interesting, -- subjects some have mountain one that you with COPD ensifentrine? follow-up. Tom have even particular per component a cells Is abstract was showing with benefited ensifentrine. there And any and greater use microliter of reason allergic in just to, data subjects [inaudible] why I a patients

David Zaccardelli

Kathy, you on want comment to that?

Kathleen Rickard

about interesting thought no is use There not it. I And we're but wouldn't exacerbation, it component. you maybe wouldn't allergic have COPD again, at reason an I'd patients. so -- time. in pattern some COPD, quite Right. most why why an in oftentimes, That COPD higher hesitate that [inaudible] be just you that an which not smaller necessarily generally some to it It's acute is, see that And eosinophils number, sure a driving around call could XX%. certainly patients the in patients, XX%,

to why So any I reason suspect would be think different there's there don't a effect.

there's not work would only we've actually subjects eosinophil have in who eosinophil. no low we and reason, fact, In high we -- both that shown

affect work of of doesn't to those ensifentrine ability it patients. the types So in

Joon Lee

And percentage contraindicated for are of COPD COPD at LAMA-LABA as dual like therapy? what look then on patients who patients, the being you

David Zaccardelli

Kathy?

Kathleen Rickard

the Is asking question? percent LABA are LAMA what Are you therapy? that for dual contraindicated

Joon Lee

LABA? are not patients of percentage being issues would LAMA what and COPD medical from or pre-existing have that preclude condition [inaudible] qualified a or them Yes,

Kathleen Rickard

in their of needs background [inaudible] and it individual so their physician question. whether frankly, the kind on a underlying forth. the really assess to that's the past, Well, status patient use depends of past, cardiovascular in Quite gone they've of and the disease broad other right. All medications

comorbidities know, all many conditions, contraindicated, there's you have certain reactions other looking patients of underlying them. know as a COPD their you perspective, that to with we hand you tell was and whole what to before the treat how from that patient certainly, the can at statistically these that a when done take of take don't are have to I of So need medical many I in that percentage we're what gestalt the for but

Joon Lee

lot question, in ATS. What data expect Yes. October? And last a of have possibly you we presentations could additional a test of

David Zaccardelli

Kathy?

Kathleen Rickard

ATS. to are be the we at going showing So we're expanding data on

So analysis, further further subgroup analysis, safety that from data further perspective. on

data, nuances extensive bringing just the more data. all Dave of said, of and So out which of is have we the amount have

we'll so the that, trying of what bring presenting that's at abstracts of and check to be also. we're And some the all facets different

Operator

follow-up have we a with Rahimi Piper from Yasmeen question Next, Sandler.

Unidentified Analyst

Hi, so much. Thanks guys.

last for one about and acceptance? game us Chris. post-NDA plan one filing just just for Sorry you me Could your to talk

Christopher Martin

Yes. Lauren, thanks.

NDA I get our think accelerate filing, continue efforts. as past we'll will -- just we to commercialization we the

is couple in a I'll talk distribution access. like of So market One buckets. on and

on Our team very get to discussions market has actively product access our been ensifentrine distribution the pathway patient. up we've for been working having diligently setting the side. in to And

how of ensifentrine to reimbursement discussions we payers as is B Part the as B covered channel. outside we'll Medicare will know the So continue continue work to Medicare be and pathway ramp up those far and finalize primary that because with Part distribution

be will that accelerate. to continues one So stream work that

a through, market marketing shaping. not shaping work are working affairs I that medical stream is or perspective from think only but important also another disease which my team

As in the first XX years. Dave to potential be new mechanism new mentioned, has product launch the over ensifentrine in

right making the idea launch. be get you that That sure expect will education we of affairs, to as marketing closer is providing market differentiate the being state and will is think sort So medical very well, ready is the really information that a as which some through from of and today done critical. the market work disease to but could us I critical something and closer efforts regarding

XXXX. So that launch ensifentrine’s we're the before setting right in market

is other the really on and the work systems stream operations think I side.

the systems our up infrastructure. commercial commercial and operations We the all actively are setting to needed support

as that quickly data that and work be so will the after finalized So as be the date. ready promoting started, product that post we're possible work PDUFA to actively a but has ENHANCE

Operator

our back session. question-and-answer like the over conference remarks. I This Zaccardelli to turn David concludes would to any closing for

David Zaccardelli

Great.

want that and patients you thank in for your the program. to participated and healthcare I the Just thank ENHANCE everyone to professionals questions,

and their support commitment. finally, Verona dedicated call. ensifentrine look And that forward concludes absolutely for further the We our talented like are potential their you extremely excited to about for thank to Operator, course, and today's shareholders of updates. team at continued the I'd of providing and

Operator

conference The has you attending now concluded. today's for Thank presentation.

disconnect. may now You

Verona Pharma (VRNA) 9 May 232023 Q1 Earnings call transcript